Development of high affinity selective VIP1 receptor agonists

Peptides

Volumn 18, Issue 10, 1997, Pages 1539-1545

  Gourlet, Philippe ^a   Vandermeers, Andre ^a   Vertongen, Pascale ^a   Rathe, Jean ^a   De Neef, Philippe ^a   Cnudde, Johnny ^a   Waelbroeck, Magali ^a   Robberecht, Patrick ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

PACAP receptors; VIP selective agonists; VIP1receptor; VIP2 receptor

Indexed keywords

ADENYLATE CYCLASE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; SECRETIN; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHICKEN; CHIMERA; ENZYME ACTIVITY; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; RNA ANALYSIS;

ADENYLATE CYCLASE; AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; CELL MEMBRANE; CELLS, CULTURED; GROWTH HORMONE-RELEASING HORMONE; IODINE RADIOISOTOPES; LIGANDS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; RECOMBINANT PROTEINS; SECRETIN; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0031418036     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(97)00228-3     Document Type: Article

References (36)

1. Bodanszky M., Natarajan S., Gardner J. D., Makhlouf G. M., Said S. I. Synthesis and some pharmacological properties of the 23-amino acids peptide 15-lysine secretin (5-27). Special role of the residue in position 15 in biological activity of the vasoactive intestinal peptide. J. Med. Chem. 21:1978;1171-1173.
2. Ciccarelli E., Svoboda M., De Neef P., Di Paolo E., Bollen A., Dubeaux C., Vilardaga J.-P., Waelbroeck M., Robberecht P. Pharmacological properties of two recombinant splice variants of the PACAP type I receptor transfected and stably expressed in CHO cells. Eur. J. Pharmacol. 288:1995;259-267.
3. Ciccarelli E., Vilardaga J.-P., De Neef P., Di Paolo E., Waelbroeck M., Bollen A., Robberecht P. Properties of the VIP-PACAP type II receptor stably expressed in CHO cells. Regul. Pept. 54:1994;397-407.
4. Couvineau A., Rouyer-Fessard C., Darmoul D., Maoret J.-J., Carrero I., Ogier-Denis E., Laburthe M. Human intestinal VIP receptor Cloning and functional expression of two cDNA encoding proteins with different N-terminal domains . Biochem. Biophys. Res. Commun. 200:1994;769-776.
5. Coy D.H., Murphy W. A., Lance V. A., Heiman M. L. Differential effects of N-terminal modifications on the biological potencies of growth hormone releasing factor analogues with varying chain lengths. J. Med. Chem. 30:1987;219-222.
6. Dimaline R., Dockray G. J. Potent stimulation of the avian exocrine pancreas by porcine and chicken vasoactive intestinal peptide. J. Physiol. Lond. 294:1979;153-163.
7. Fahrenkrug J. Vasoactive intestinal polypeptide measurement, distribution and putative neurotransmitter function . Digestion. 19:1979;149-169.
8. Gossen D., Buscail L., Cauvin A., Gourlet P., De Neef P., Rathé J., Robberecht P., Vandermeers-Piret M-C., Vandermeers A., Christophe J. Amino acid sequence of VIP, PHI and secretin from the rabbit small intestine. Peptides. 11:1990;123-128.
9. Gourlet P., De Neef P., Woussen-Colle M-C., Vandermeers A., Vandermeers-Piret M-C., Robberecht P., Christophe J. The activation of adenylate cyclase by pituitary adenylate cyclase activating polypeptide (PACAP) via helodermin-preferring VIP receptors in human SUP-T1 lymphoblastic membranes. Biochim. Biophys. Acta. 1066:1991;245-251.
10. 16 in VIP, PACAP and secretin on ligand affinity of the receptors. Biochim. Biophys. Acta. 1314:1996;267-273.
11. 2 receptor subclass. Peptides. 18:1997;403-408.
12. Inagaki N., Yoshida H., Mizuta M., Mizuno N., Fujii Y., Gonoi T., Miyazaki J.-L. , Seino, S. Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. Proc. Natl. Acad. Sci. USA. 91:1994;2679-2683.
13. Ishihara T., Shigemoto R., Mori K., Takahashi K., Nagata S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron. 8:1992;811-819.
14. Ishihara T., Nakamura S., Kaziro Y., Takahashi T., Takahashi K., Nagata S. Molecular cloning and expression of a cDNA encoding the secretin receptor. EMBO J. 10:1991;1635-1641.
15. Krempels K., Usdin T. B., Harta G., Mezey E. PACAP acts through VIP type 2 receptors in the rat testis. Neuropeptides. 29:1995;315-320.
16. Laburthe M., Amiranoff B., Boige N., Rouyer-Fessard C., Tatemoto K., Moroder L. Interaction of GRF with VIP receptors and stimulation of adenylate cyclase in rat and human intestinal epithelial membranes. Comparison with PHI and secretin. FEBS Lett. 159:1983;89-92.
17. 2 receptor molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide . FEBS Lett. 334:1993;3-8.
18. Nilsson A. Isolation, aminoacid composition and terminal amino acid residues of the vasoactive octacosapeptide from chicken intestine. Partial purification of chicken secretin. FEBS Lett. 47:1974;284-289.
19. Rawlings S. R., Hezareh M. Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/Vasoactive intestinal polypeptide receptors Actions on the anterior pituitary gland . Endocrine Rev. 17:1996;4-29.
20. Robberecht P., Gourlet P., Vertongen P., Svoboda M. Characterization of the VIP receptor from SUP Tl lymphoblasts. Advan. Neuroimmunol. 6:1996;49-57.
21. Robberecht P., Waelbroeck M., De Neef P., Tastenoy M., Gourlet P., Cogniaux J., Christophe J. A new type of functional VIP receptor has an affinity for helodermin in human SUP-T1 lymphoblasts. FEBS Lett. 228:1988;351-355.
22. 1 lymphoma cell membranes. Regul. Pept. 26:1989;117-126.
23. Robberecht P., Gourlet P., De Neef P., Woussen-Colle M.-C., Vandermeers-Piret M.-C., Vandermeers A., Christophe J. Receptor occupancy and adenylate cyclase activation in AR 4-2J rat pancreatic acinar cell membranes by analogs of Pituitary Adenylate Cyclase-Activating Peptides amino-terminally shortened or modified at position 1, 2, 3, 20, or 21 Mol. Pharmacol. 42:1992;347-355.
24. 2 as a GRF antagonist on membranes . Endocrinology. 117:1985;1759-1764.
25. Salomon Y., Londos C., Rodbell M. A highly sensitive adenylate cyclase assay. Anal. Biochem. 58:1974;541-548.
26. Sreedharan S. P., Patel D. R., Huang J.-X., Goetzl E. J. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem. Biophys. Res. Commun. 193:1993;546-553.
27. Svoboda M., Tastenoy M., Van Rampelbergh J., Goossens J.-F., De Neef P., Waelbroeck M., Robberecht P. Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem. Biophys. Res. Commun. 205:1994;1617-1624.
28. Usdin T. B., Mezey E., Button D.C., Brownstein M.J., Bonner T.I. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology. 133:1993;2861-2870.
29. Van Valen F., Jurgens H., Winkelmann W., Keck E. Vasoactive intestinal peptide receptor regulation of cAMP accumulation and glycogen hydrolysis in the human Ewing's sarcoma cell line WE-68. Cell. Signal. 1:1989;435-446.
30. Vertongen P., Delhase M., Rajas F., Trouillas J., Hooghe-Peters E., Svoboda M., Robberecht P. Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes are differently expressed in rat transplanted pituitary tumours (SMtTW) and in the normal gland. J. Mol. Endocrinol. 16:1996;239-248.
31. Vertongen P., D'Haens J., Michotte A., Velkeniers B., Van Rampelbergh J., Svoboda M. ; P. Robberecht, P. Expression of Pituitary Adenylate Cyclase Activating Polypeptide and receptors in human brain tumors. Peptides. 16:1995;713-719.
32. Vertongen P., Devalck C., Sariban E., De Laet M.-H., Martelli H., Paraf F., Hélardot P., Robberecht P. Pituitary Adenylate Cyclase Activating Peptide and its receptors are expressed in human neuroblastomas. J. Cell. Physiol. 167:1996;36-46.
33. 2 receptor. Neuropeptides. 30:1996;491-496.
34. Vilardaga J. P., Ciccarelli E., Dubeaux C., De Neef P., Bollen A., Robberecht P. Properties and regulation of the coupling to adenylate cyclase of the secretin receptor stably transfected in CHO cells. Mol. Pharmacol. 45:1994;1022-1028.
35. Vilardaga J.-P., De Neef P., Di Paolo E., Bollen A., Waelbroeck M., Robberecht P. Properties of chimeric and VIP receptor proteins indicate the importance of the N-terminal domain for ligand discrimination, Biochem. Biophys. Res. Commun. 211:1995;885-891.
36. 2 as a VIP antagonist . Endocrinology. 116:1985;2643-2649.